Daniel Brook

Daniel Brook

Partner, London

Email daniel.brook@​hoganlovells.com

Phone +44 20 7296 5484

Fax +44 20 7296 2001

LanguagesEnglish

Practice groupIntellectual Property

A 'very sharp' up-and-coming partner who is 'developing a very good practice.'

Legal500

Daniel is a patent litigator in the UK.  He acts for clients such as Merck, Lilly, Amgen and BMS.  Recent key cases include Schutz v Werit (Supreme Court), Actavis v Lilly (Court of Appeal and currently pending before the Supreme Court), and BMS v Teva (availability of interim injunctions).

He has experience with each of the major patent jurisdictions in Europe. He regularly manages cross border patent litigation for clients on their most important products and has been involved in a number of leading cases.

Daniel is ranked by Chambers UK - 'Clients commend his 'high-quality counselling' and his 'clear, well-structured' communications.', Legal 500, MIP IP Stars and IAM Patent 1000.

Awards and recognitions

2013

Legal 500, Pharmaceuticals and biotechnology

2013 onwards

IAM Patent 1000

2015

UK, Rising Star 2013 and Super Lawyer 2015
SuperLawyers

2013

Legal 500, Intellectual Property, 2013 onwards

2014

Chambers UK, Intellectual Property: Patent Litigation, 2014 onwards

Education and admissions

Education

M.A. Natural Sciences - Chemistry, University of Cambridge, 1999

M.Sci, University of Cambridge, 1999

Memberships

AIPPI Council Member

CIPA

EPLAW

Representative experience

Acting for MSD in relation to patent challenges around its products including simvastatin, lovastatin, alendronate and raltegravir.

Acting for Lilly in relation to patent challenges around its oncology products including pemetrexed and gemcitabine.

Acting for BMS in relation to patent challenges around its HIV products, efavirenz and atazanavir.

Acting for a number of electronic clients including ZTE, Qualcomm and BlackBerry on European patent litigation matters.

Loading data